Centre Hospitalier Metropole Savoie

Clinical research here focuses strongly on neoplasms, with studies centered on small cell lung cancer and prostate cancer. The trials are designed to evaluate new treatment combinations and compare how well they control advanced disease, especially in patients with limited treatment options.

• Testing whether new cancer therapies can improve outcomes in extensive-stage small cell lung cancer
• Assessing treatment effectiveness for metastatic prostate cancer in patients with reduced functional ability
• Exploring better ways to manage advanced solid tumors through combination approaches

This work reflects a clear interest in improving both disease control and patient benefit in difficult-to-treat oncology settings.

A major part of the site’s trial activity is dedicated to hemic and lymphatic diseases, especially follicular lymphoma, marginal zone lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. These studies aim to improve treatment response, safety, and long-term disease control in blood cancers.

• Evaluating new options for relapsed or refractory follicular lymphoma and marginal zone lymphoma
• Studying treatment strategies for newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
• Comparing newer therapies with established lymphoma and leukemia treatment approaches

The Centre Hospitalier Metropole Savoie contributes to research that seeks more effective and better-tolerated care for patients with complex hematologic cancers.

Another important area of study involves hemophilia A and hemophilia B, with attention to how preventive treatment supports joint health over time. The research is aimed at improving disease monitoring and understanding the impact of ongoing prophylaxis in patients living with bleeding disorders.

• Assessing joint status in patients receiving preventive therapy for hemophilia
• Using ultrasound to better understand musculoskeletal outcomes in long-term care
• Supporting improved follow-up for people with inherited bleeding disorders

These studies combine hematology and diagnostic care, with the goal of making treatment follow-up more informative and patient-centered.

The site is also involved in trials that test how newer targeted therapies perform when combined with standard treatments. These studies span lymphoma, leukemia, and other blood cancers, with a focus on safety, tolerability, and improved disease control.

• Studying whether new combinations can improve outcomes in follicular lymphoma
• Evaluating treatment response in indolent lymphoma and related subtypes
• Comparing novel approaches with established regimens to find more effective care

This research highlights a broader effort in clinical oncology to refine treatment strategies and expand options for patients with relapsed or newly diagnosed disease.